Bullish
Eli Lilly's Omvoh shows efficacy in ulcerative colitis and Crohn’s disease
Eli Lilly's Omvoh (mirikizumab-mrkz) has demonstrated significant efficacy in treating moderately to severely active ulcerative colitis and Crohn's disease. Recent data analyses revealed that over 27% of patients achieved comprehensive disease control in ulcerative colitis, and a substantial proportion reached deep remission in Crohn's disease. These findings underscore Omvoh's potential to transform treatment approaches for these conditions.
Key points
- Omvoh achieves over 27% comprehensive disease control in ulcerative colitis patients.
- Significant proportion of Crohn's disease patients attain deep remission with Omvoh.
- Eli Lilly confirms date and conference call for third-quarter 2026 financial results announcement.
Sources
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one yearPR Newswire · October 15, 2026
- Lilly confirms date and conference call for third-quarter 2026 financial results announcementPR Newswire · October 15, 2026
AI-generated from public news sources. Not financial advice.
